A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

BACKGROUND: Ki67 is widely used in order to distinguish the “A” and “B” subtypes of luminal-type breast cancer. This study aimed to validate the prognostic value of adding p53 to Ki67 for characterizing luminal-type breast cancer. METHODS: Immunostaining for Ki67, p53, and the molecular markers HER2...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Takayuki, Iwaya, Keiichi, Moriya, Tomoyuki, Yamasaki, Tamio, Tsuda, Hitoshi, Yamamoto, Junji, Matsubara, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577510/
https://www.ncbi.nlm.nih.gov/pubmed/23384409
http://dx.doi.org/10.1186/1472-6890-13-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577510/
https://www.ncbi.nlm.nih.gov/pubmed/23384409
http://dx.doi.org/10.1186/1472-6890-13-5

Ejemplares similares